glp 1 drugs and rheumatoid arthritis ACR 2025: GLP-1 Reduce Flares Microdosing GLP-1 for Rheumatoid Arthritis:
Description
RYs current A1C is 7.5%
Side Effects and Safety Common side effects include gastrointestinal discomfort
Lilly Launches Trulicity in the US First Ever Ready-to-Use Once-Weekly GLP-1 Receptor Agonist Eli Lilly launches Trulicity in the US first ready-to-use once-weekly GLP-1, available with a savings program for commercially insured patients
P = 0.0006), and dulaglutide in REWIND trial (HR 0.88
Specifically, the HR for HHF was 0.20 (95% CI 0.070.60) with GLP-1RAs and 0.77 (95% CI 0.640.92) without GLP-1RAs ( P -value for interaction 0.014)
